Your online news alert guide to stocks and shares and more Wednesday, 02 September 2009

Stocks Shares News Alerts

ALL the included information is gleaned from internet sources including spam emails. We make no recommendations on the contents and are not responsible for the accuracy of the information or your actions in acting upon any information on this website. If we feature articles or information that you believe belongs to you and do not want us to publish the information, please describe it in an email to bullish@financier.com and we will immediately remove it. If you have information you would like published please submit to us for consideration.

BULL DISCUSSION FORUM HERE

STOCK ALERTS

Information within contains 4rward l0 0king statements within the meaning of Section 27A of the Securities Act of nineteen thirty three andSection 21B of the Securities Exchange Act of nineteen thirty four. Any
statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or
future events or performance are not statements of historical fact and may be 4rward 1o0king statements.4rward lo oking statements are based on
expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated. As with many micr ocap st0c ks, today's co mpany has disclosable material items
you need to consider in order to make an informed and intelligent in_vestment decision. These items include: A nominal cash position and a
going concern opinion from its auditor. It is an operating Company. The company is going to need financing. If that financing does not occur, the
company may not be able to continue as a going concern in which case you could lose your entire in-vestment. The publisher of this new sletter does
not represent that the information contained in this messa ge states all material facts or does not omit a material fact necessary to make the
statements therein not misleading. All information provided within this site pertaining to in-vesting, st0cks, secur1ties must be understood as
information provided and not invest ment advice. Remember a thorough due diligence effort, including a review of a comp any's filings when
available, should be completed prior to in_ve sting. The publisher of this newsletter advises all readers and subscribers to seek advice from a
registered professional secu rities representative before deciding to trade in s t0cks featured within this e_m ail. None of the material within this
report shall be construed as any kind of in_vestm ent advice or solicitation. Many of these companies are on the verge of bankruptcy. You
can lose all your mo ny by inve sting in this st0 ck. The publisher of this newsl etter is n0t a reg1stered in-vest ment adv is0r. Subscribers should
not view information herein as legal, tax, accounting or invest ment advice. All information in this report was gathered from public sources, including but not limited to
Company Press Releases. Use of the information in this site constitutes your acceptance of these terms.

Your online news alert guide to stocks and shares and more

Stocks
Shares
News
Alerts

ARCHIVE - 3 Unknown Penny Stocks Ready To Surge

By Brian T Mikes Editor, Dynamic Wealth Report

Unknown Stock #1: A Tiny Pharmaceutical Company Treating A Widespread Problem
Does your stomach hurt occasionally? If not, your neighbors’ probably are. Possibly a co-worker or two as well. It’s not exactly the conversation you have with casual acquaintances… or anyone for that matter.

Despite its somewhat embarrassing nature, it is believed more than 20% of all Americans suffer from recurring stomach problems. If you take a visit to any drugstore, you’ll see the section on stomach medications is the largest in the entire store! You’ll see medications for IBS, constipation, gas, bloating, heartburn, diarrhea, and on and on.

The doctors call these ‘gastrointestinal problems’ and often have a tough time diagnosing and treating these problems effectively. Many chronic sufferers are now told they have IBS- a ‘catch all’ for a number of different stomach ailments.

As you can see, this is a huge market.

“IBS statistics are sobering: An estimated 35 million Americans have the disease. It ranks second only to the common cold as a cause of lost work time and accounts for approximately 3 million physician visits in the United States every year.” – Today’s Dietician, February, 2003

Further, did you know in 2002 almost 400,000 people were hospitalized for constipation? Physician visits for this problem average 2.5 million per year. Can you imagine the number that never see a doctor because of embarrassment?

So what can we learn from these statistics?

Simply, millions of people need drugs to help treat these stomach problems. Current medications and treatments are just not that effective for the long-term recovery of most people with chronic stomach ‘issues’.

As such, there is a gigantic need for medicines that can help alleviate and cure these disorders.

One company we found in this area, Sucampo Pharmaceuticals (symbol:SCMP), develops and markets drugs to treat all of these problems and more.

Sucampo’s key product is AMITIZA. Doctor’s use it to treat constipation. The drug is also being used in Phase III clinical trials for treatment of IBS. The drug must work wonders- prescriptions for AMITIZA are increasing nearly every quarter.

And if AMITIZA is approved for the treatment of IBS, look out, revenues will skyrocket!

Now, constipation and IBS aren’t the only focus of Sucampo. They're also working on drugs to treat other ailments such as ulcers, pulmonary disease, and even Alzheimer’s. This kind of diversity is good for a small pharmaceutical company. You never know where the next big drug breakthrough will come from.

Sucampo’s numbers are great already. They’ve got solid revenue growth, and are spending aggressively on Research & Development. In fact R&D spending has recently been increasing by over $3 million a quarter because of ongoing clinical trials. These R&D dollars are an investment that will hopefully pay big dividends down the road.

Year over year, the company’s growing revenues by over 12%. Not bad in a tough economic environment. They’re also sitting on over $100 million in cash, not bad for a ‘small’ pharmaceutical company..

Overall, we believe the company is well positioned for long-term growth. With one hot selling product and several more in development, it won’t be long before we see some serious growth. And with this serious growth, we expect to see some serious appreciation in the stock.

Unknown Stock #2: A Specialized Hospital Play on the Aging of American

"National health-care spending, which hit nearly $1.8 trillion in 2004, will increase as a percentage of GDP by 22 percent over the next 10 years. For that the health-care industry can thank the boomers, who are just beginning to enter the time of their lives when drug, hospital and other expenditures rise dramatically." –CNN Money

It is estimated that between 1946 and 1964, 79.6 million people were born in the United States. These ‘Baby Boomers’ were conceived after World War II and represent the largest segment of the American population.

The effect this group of people is having on the economy is profound. Now between the ages of 45 and 63, the ‘Baby Boomers’ are getting to the age where medical and healthcare issues begin to take center stage. More and more of the boomers will want and/or need specialized surgeries.

This older group of people will need medical procedures that help them lose weight, replace joints, fix bad backs, deal with strokes, and reduce pain. And with the way the current healthcare system is set-up, many of them will look for better and easier solutions than what is ‘usually’ available.

This is where specialized-surgery hospitals like Dynacq Healthcare (symbol:DYII) come in. Dynacq is a developer and operator of acute-care hospitals in Texas and Louisiana.

These cutting-edge hospitals handle specialized surgeries in the orthopedic, bariatric, and neuro-spine disciplines. They’re typically part-owned by the surgeons who work there- giving them a vested interest in the success of the hospital as a whole.

We think you’ll start to see more and more of these ‘specialized’ hospitals cropping up all over the United States and the entire world (Dynacq has a joint venture in the works to build a hospital in Shanghai, China). Besides the immense benefits for patients, these types of companies are extremely profitable.

Dynacq has a profit margin of nearly 24% and enjoys quarterly revenue growth of over 12%. Virtually all of the financial metrics used to evaluate stocks are positive for DYII. They have a low price-to-earnings ratio, a low price-to-sales ratio, good free cash flow, and superior return on equity. They also have $32 million in cash.

Once Wall Street recognizes the impressive financial condition and performance of this company, I think you’ll see DYII shares really take off. There aren’t a lot of penny stocks that offer tremendous value, but I think Dynacq definitely is one of them.

Unknown Stock #3: The Stock Wall Street Abandoned -But Is About To Rediscover
We all know the story. In the late 90s the internet craze hot the stock markets. Any company with a '.com' at the end of its name saw its stock skyrocket on a daily basis. You had companies that just formed having billion-dollar valuations. ‘Internet’ millionaires were being created at an unprecedented rate.

But everyone forgot one minor thing.

None of these companies were making money nor did they having any prospect of doing so.

Once this fundamental law of capitalism was remembered, the shares of these internet companies came crashing down to Earth. Most went out of business, never to be heard from again.

But what about the ones that survived? What about the companies that actually offered a useful product? Was the proverbial baby thrown out with the bathwater?

For EasyLink Services (symbol:ESIC) we think this may be the case.

EasyLink Services is a company that facilitates the electronic exchange of documents between companies, departments, and customers. In a nutshell, they simplify the delivery of purchase orders, shipping notices, business reports, and faxes.

Going into how they do this is beyond the scope of this report. Just know that EasyLink deals with both supply chain messaging and on-demand messaging for hundreds of different companies in sectors as diverse as apparel, consumer goods, financial, grocery, media, pharmaceuticals, publishing, retail, and transportation.

Unlike many of its internet boom predecessors, ESIC actually makes money (a novel concept-I know). Their revenue is approaching $100 million a year. Their gross margin is an unbelievable 67.9%.

In addition, their quarterly revenue growth is well over 300% and their earnings growth is over 1,000%. This performance has allowed EasyLink to amass $27 million in cash (and garner both a low PE and price-to-sales number).

So yes, this company has a real business plan and is very, very profitable.

Some of you may be wondering why the stock is priced so low? After all, it was trading at over $100 per share during the dot com days.

That’s a good question. A stock that is growing this fast and making money should be valued much higher. We think this will indeed be the case as EasyLink continues to grow. At some point, investors and institutions will start snapping up shares of this promising company.

Make sure you get in before that happens!

How To Turn $300 Into $1.3 Million With Penny Stocks
Before concluding our report we wanted to do the math on how it would be possible to turn $300 into $1.3 million. Now before we run the numbers, you need to know that getting a return this high would be difficult, but not impossible. Most investors would be happy to get just a fraction of these gains.

	Start Amount	Return	Gain	Ending Amount
Stock #1	$300	852%	$2,556	$2,856
Stock #2	$2,856	3,428%	$97,903	$100,759
Stock #3	$100,759	1,256%	$1,265,541	$1,366,300

So there you have it. To turn $300 into $1.3 million, you’d need 3 consecutive returns of 852%, 3,428% and 1,256%. Difficult to do, yes. Impossible, no.

One thing is certain however. If you’re going to attempt gains like this, you’ll need to do it with penny stocks. It’s very difficult to register gains of 1,000% to 4,000% with blue-chip stocks like General Electric and Microsoft. You’ve got to find penny stocks that turn into the next General Electric and Microsoft.

And you do that by finding high-quality companies with real products and real potential. They’re out there- it’s just a matter of finding them!

Sincerely,

Brian T Mikes, Dynamic Wealth Report

P.S. Our own penny stock expert Robert Morris has just put together a report on a little-known SEC regulation that can send penny stock prices through the roof. It may be the quickest and easiest way to turn $300 into $1.3 million that we've ever seen.